|
AstraZeneca presents new results identifying severe asthma patients who would benefit most from benralizumab
|
12 September 2017 |
|
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
|
06 September 2017 |
|
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
|
29 August 2017 |
|
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
|
24 August 2017 |
|
US FDA accepts regulatory submission for acalabrutinib and grants Priority Review
|
02 August 2017 |
|
AstraZeneca and Merck establish strategic oncology collaboration
|
27 July 2017 |
|
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
|
08 June 2017 |
|
AstraZeneca enters agreement with Recordati for Seloken in Europe
|
22 May 2017 |
|
Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
|
12 May 2017 |
|
AstraZeneca marks a key milestone with the ‘topping out’ of new global R&D centre and HQ in Cambridge, UK
|
02 May 2017 |